Skip to main content
. 2022 Jan 4;14(1):230. doi: 10.3390/cancers14010230

Figure 2.

Figure 2

Time dependent uptake of [125I]-PARPi-01 (0.5 MBq/mL (for 0.5 × 106 cells i.e., 1 Bq/cell); 1, 4, and 24 h, with black, yellow, and red columns, respectively) upon pre-treatment with different chemotherapeutic strategies, such as olaparib (1 µM, 72 h), talazoparib (10 nM, 72 h), dinaciclib (5 µM, 72 h) temozolomide (50 µM, 48 h) and Dox-NP (doxorubicin, 100 nM, 6 h), in each cell line. % Uptake normalised to the untreated samples at 1 h post incubation. Significance was tested using two-way ANOVA with Dunnet’s post-hoc test (n = 3, * p < 0.05).